← Search & browse all drugs

cendakimab

L04AC27

Forms & Strengths

Solution for injection: 300mg/2mL and 450mg/3mL
Single-dose prefilled syringe or autoinjector

Adult Dosing

Loading dose: 450mg at weeks 0, 1, and 2
Maintenance dose: 450mg every 4 weeks
Subcutaneous injection, rotate injection sites

Pediatric Dosing

No established pediatric dosing recommendations
Use in pediatric populations not well studied

Indications

Treatment of moderate to severe plaque psoriasis in adults
May be used for other inflammatory conditions as part of ongoing research

Mechanism of Action

Human monoclonal antibody targeting IL-17A
Blocks interaction of IL-17A with its receptor
Reduces inflammation and prevents disease progression

Contraindications

Hypersensitivity to cendakimab or excipients
Active tuberculosis or history of recurrent infections

Adverse Reactions

Injection site reactions: pain, redness, swelling
Upper respiratory tract infections, such as nasopharyngitis
Gastrointestinal symptoms: nausea, diarrhea

Drug Interactions

Avoid concomitant use with live or live attenuated vaccines
Caution with concurrent use of immunosuppressants or biologics
Monitor CYP450 substrates, such as warfarin or cyclosporin

Curated Content: Needs Vetting Before Put to Clinical Use